Second Lucentis Phase III Study Meets Primary Endpoint For Improved Vision In Patients With Diabetic Macular Edema (DME)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the second of two Phase III trials evaluating Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME) met its primary endpoint...